Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended		25 Months Ended	166 Months Ended
	Sep. 30, 2011 Successor	Sep. 30, 2010 Successor	Sep. 30, 2011 Successor	Aug. 31, 2009 Predecessor	Aug. 31, 2009 Predecessor Series A Preferred Stock	Aug. 31, 2009 Predecessor Series B Preferred Stock	Aug. 31, 2009 Predecessor Series D Preferred Stock [Member]
Cash flows from operating activities:
Net loss attributable to Fibrocell Science, Inc. common shareholders	$ (20,293,605)	$ (8,281,245)	$ (38,275,135)	$ (115,322,121)
Adjustments to reconcile net loss to net cash used in operating activities:
Reorganization items, net	0	0	72,477	(74,648,976)
Expense related to equity awards and issuance of stock	2,639,965	842,940	4,513,724	10,608,999
Warrant expense (income)	(814,676)	(1,560,757)	(30,360)	0
Derivative revaluation expense	5,865,710	0	5,865,710	0
Uncompensated contribution of services	0	0	0	755,556
Depreciation and amortization	75,702	5,612	83,787	9,091,990
Provision for doubtful accounts	(14,766)	(12,839)	(69,203)	337,810
Provision for excessive and/or obsolete inventory	(23,654)	(51,165)	(72,356)	259,427
Amortization of debt issue costs	0	0	0	4,107,067
Amortization of debt discounts on investments	0	0	0	(508,983)
Loss on disposal or impairment of property and equipment	0	0	0	17,668,477
Foreign exchange gain on substantial liquidation of foreign entity	(3,110)	(3,031)	(10,796)	(2,256,408)
Net (loss) income attributable to noncontrolling interest	40,743	37,247	108,134	(1,799,523)
Change in operating assets and liabilities, excluding effects of acquisition:
Decrease (increase) in accounts receivable	10,239	3,783	81,469	(91,496)
Decrease (increase) in other receivables	3,981	(105)	4,688	218,978
Decrease (increase) in inventory	(33,339)	69,086	25,043	(455,282)
Decrease (increase) in prepaid expenses	(816,928)	(37,812)	(1,019,034)	34,341
Decrease in other assets	0	0	4,120	71,000
Increase (decrease) in accounts payable	(45,910)	828,353	912,814	57,648
Increase in accrued expenses, liabilities subject to compromise and other liabilities	1,118,057	1,228,707	1,948,403	3,311,552
Increase (decrease) in deferred revenue	12,500		12,500	(50,096)
Net cash used in operating activities	(12,279,091)	(6,931,226)	(25,844,015)	(148,610,040)
Cash flows from investing activities:
Acquisition of Agera, net of cash acquired	0	0	0	(2,016,520)
Purchase of property and equipment	(786,441)	(29,675)	(816,115)	(25,515,170)
Proceeds from the sale of property and equipment, net of selling costs	0	0	0	6,542,434
Purchase of investments	0	0	0	(152,998,313)
Proceeds from sales and maturities of investments	0	0	0	153,507,000
Net cash used in investing activities	(786,441)	(29,675)	(816,115)	(20,480,569)
Cash flows from financing activities:
Proceeds from convertible debt	0	0	0	91,450,000
Offering costs associated with the issuance of convertible debt	0	0	0	(3,746,193)
Proceeds from notes payable to shareholders, net	0	0	0	135,667
Proceeds from the issuance of redeemable preferred stock net					12,931,800	0	0
Deposit received for issuance of shares in October 2010	0	130,000	0	0
Proceeds from the exercise of warrants	2,418,646	0	2,418,646	0
Proceeds from the issuance of common stock, net	20,679,265	3,469,400	25,948,665	93,753,857
Costs associated with secured loan and debtor-in-possession loan	0	0	0	(360,872)
Proceeds from secured loan	0	0	0	500,471
Proceeds from debtor-in-possession loan	0	0	0	2,750,000
Payments on insurance loan	(56,911)	(47,795)	(142,485)	(79,319)
Principal payments on 12.5% note payable	(1,283,321)	0	(1,283,321)	0
Cash dividends paid on preferred stock	(559,229)	(139,750)	(698,979)	(1,087,200)
Cash paid for fractional shares of preferred stock	0	0	0	(38,108)
Merger and acquisition expenses	0	0	0	(48,547)
Repurchase of common stock	0	0	0	(26,024,280)
Net cash provided by financing activities	27,034,430	5,800,023	40,477,476	170,137,276
Effect of exchange rate changes on cash balances	3,756	3,473	12,770	(36,391)
Net increase (decrease) in cash and cash equivalents	13,972,654	(1,157,405)	13,830,116	1,010,276
Cash and cash equivalents, beginning of period	867,738	1,362,488	1,010,276
Cash and cash equivalents, end of period	14,840,392	205,083	14,840,392	1,010,276
Supplemental disclosures of cash flow information:
Predecessor cash paid for interest	435,096	0	435,096	12,715,283
Successor cash paid for dividends	559,229	139,750	698,979	0
Non-cash investing and financing activities:
Predecessor deemed dividend associated with beneficial conversion of preferred stock	0	0	0	11,423,824
Predecessor preferred stock dividend	0	0	0	1,589,861
Successor accrued preferred stock dividend	431,679	85,183	431,679	0
Predecessor uncompensated contribution of services	0	0	0	755,556
Predecessor common stock issued for intangible assets	0	0	0	540,000
Predecessor common stock issued in connection with conversion of debt	0	0	0	10,814,000
Predecessor equipment acquired through capital lease	0	0	0	167,154
Successor/Predecessor financing of insurance premiums	0	0	178,582	87,623
Successor issuance of notes payable	0	0	0	6,000,060
Successor common stock issued in connection with reorganization	0	0	0	5,472,000
Successor intangible assets	0	0	0	6,340,656
Successor deferred tax liability in connection with fresh-start	0	0	0	2,500,000
Elimination of Predecessor common stock and fresh-start adjustment	0	0	0	14,780,320
Successor subscription receivable	2,038,733	792,000	2,038,733	0
Successor accrued warrant liability	4,994,307	5,579,319	12,381,509	0
Successor conversion of preferred stock derivative balance into common stock	7,237,210	0	7,601,210	0	0
Successor exercise of warrants	4,841,519	0	4,841,519	0
Successor accrued derivative liability	$ 308,060	$ 0	$ 2,428,420	$ 0